ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01EB01 | G | Gefitinib - 250mg | 10135 | 161719/1 | GEFITINIB BIOGARAN | 250mg | 30 | Tablet, coated | Oral | Commercial and Trading Ressources SAL (CTR) | Remedica Ltd | Cyprus | 81,299,103 L.L | 2.44 | E2 | Laboratoires Biogaran | France | 2/5/2024 | 0 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01EB01 | B | Gefitinib - 250mg | 6238 | 218930/10 | IRESSA | 250mg | 30 | Tablet, fim coated | Oral | Omnipharma | NIPRO Pharma Corporation, Kagamiishi Plant | Japan | 135,027,509 L.L | 2.44 | E2 | AstraZeneca UK Ltd | UK | 2/5/2024 | 0 |
L01EB01 | G | Gefitinib - 250mg | 10823 | 95720/1 | APO-GEFITINIB | 250mg | 30 | Tablet | Oral | Promopharm S.A.R.L. | Apotex Inc | Canada | 88,933,548 L.L | 2.44 | E2 | Apotex Inc | Canada | 2/5/2024 | 0 |
L01EB01 | G | Gefitinib - 250mg | 10728 | 152119/1 | GEFITINIB ARROW | 250mg | 30 | Tablet, coated | Oral | Darapharma S.A.L. | Remedica Ltd | Cyprus | 79,673,676 L.L | 2.44 | E2 | Arrow Génériques | France | 2/5/2024 | 0 |
L01EB01 | G | Gefitinib - 250mg | 10135/388 | 161719/1 | GEFITINIB BIOGARAN | 250mg | 30 | Tablet, coated | Oral | Commercial and Trading Ressources SAL (CTR) | Remedica Ltd | Cyprus | L.L | 2.44 | E2 | Laboratoires Biogaran | France | 2/5/2024 |